Genomics & Genetics Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genomics & Genetics Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Therapy
IND application filed for anticancer compound XL999
July 30th, 2004
Exelixis, Inc., (EXEL) has submitted an investigational new drug application (IND) to the U.S. Food and Drug Administration (FDA) for XL999, a proprietary anticancer compound. Preclinical studies with XL999 have demonstrated potent inhibition in vivo against multiple receptor tyrosine kinases (RTKs) that are implicated in tumor angiogenesis, or the development and maintenance of tumor vasculature. Pending clearance by the U.S. Food and Drug Administration, the company intends to initiate a phase I clinical trial. XL999 is one of several Spectrum Selective Kinase Inhibitors (SSKI) in Exelixis' product pipeline. Each SSKI has a different RTK inhibition...
Source: Genomics & Genetics Weekly (2004-07-30)
|
